• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Eli Lil­ly part­ners at CRUK tack­le the first hu­man study of a new p53-tar­get­ed can­cer drug

8 years ago
R&D

Paratek shares soar as the an­tibi­ot­ic de­vel­op­er posts a ‘for sale’ sign

8 years ago
Deals

PhI­II bust forces Ul­tragenyx to scrap drug for rare mus­cle dis­ease

8 years ago
R&D

In­di­v­ior opens up a $30M R&D cen­ter; Lil­ly strikes dis­cov­ery deal with Topas

8 years ago
News Briefing

New docs spot­light the FDA’s failed at­tempt to get Sarep­ta’s flawed Duchenne study re­tract­ed

8 years ago
Pharma

FDA throws up an­oth­er road­block to Car­diome, 9 years af­ter re­ject­ing its drug

8 years ago
Pharma

The best — and worst — biotech IPOs in the class of 2017

8 years ago
Financing

Big names, big com­pa­nies back a cell ther­a­py start­up run by a high-pro­file re­gen­er­a­tive med ex­pert

8 years ago
Startups
Cell/Gene Tx

Build­ing up its I/O ops, CRISPR Ther­a­peu­tics al­lies with Marcela Maus at Mass Gen­er­al

8 years ago
Pharma

Ju­rors: In the end, Mar­tin Shkre­li was done in by his own in­flat­ed ego

8 years ago
People

Per­son­al turf is ‘out,’ com­mu­ni­ty work­places are ‘in’ at the new Roche neigh­bor­hood

8 years ago
Pharma

Shire CFO to jump ship; Akari taps Zealand vet as new CEO

8 years ago
News Briefing

Af­ter two years of ne­go­ti­a­tions, FDA gets its user fee pro­grams au­tho­rized through 2022

8 years ago
Pharma

Iron­wood looks to boost gout fran­chise as FDA de­liv­ers OK for Duza­l­lo

8 years ago
Pharma

Strug­gling As­traZeneca ups the ante on mR­NA pipeline work

8 years ago
R&D
Pharma

Top 10 pipeline blowups, set­backs and sna­fus in H1 2017

8 years ago
R&D
Special

Sam­sung Bioepis switch­es gears, moves from knock­offs to new drugs with fast-chang­ing Take­da

8 years ago
Pharma

Medi­vir out-li­cens­es hep C drug to Chi­na’s As­cle­tis; Cel­lec­tis launch­es pi­o­neer­ing UCART123 US study

8 years ago
News Briefing

Biotech M&A bare­ly show­ing sign of a pulse so far in 2017

8 years ago
Deals

Pre­emp­tive sham­ing as­sault on No­var­tis’ CAR-T pi­o­neer un­der­scores a dis­con­nect on R&D costs

8 years ago
Bioregnum
Opinion

With CAR-T mar­ket­ing loom­ing, ear­ly study high­lights po­ten­tial of TCR en­gi­neer­ing

8 years ago
R&D

Thomas Wynn makes the leap out of the NIH and in­to a lead dis­cov­ery post for Pfiz­er

8 years ago
Peer Review

Watch out Tesaro, As­traZeneca and Mer­ck get FDA OK for broad use of Lyn­parza

8 years ago
Pharma

Pfiz­er's CD22-tar­get­ed can­cer drug in­o­tuzum­ab wins an ac­cel­er­at­ed OK at FDA

8 years ago
R&D
Pharma
First page Previous page 1089109010911092109310941095 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.